Skip to content

Bullous versus nonbullous pemphigoid: what makes the blister?

Gene expression and eosinophils/IL-31 in bullous versus nonbullous pemphigoid: what makes the blister?

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON20573
Enrollment
10
Registered
2018-04-12
Start date
2018-06-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bullous pemphigoid, nonbullous pemphigoid, bulleus pemfigoïd, niet-bulleus pemfigoïd.

Interventions

no interventions will be used. we will collect biopsies from patients that are included.

Sponsors

University Medical Center Groningen
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Written informed consent. 2. ≥18 years old. 3. Patients that are diagnosed with pemphigoid (bullous or nonbullous) ¡Ü1 month ago, or pemphigoid patients that were in complete remission without therapy and experience a relapse can be included. [The following diagnostic criteria are used for pemphigoid: a positive DIF with linear IgG and/or C3c along the BMZ, and/or positive IIF on SSS or monkey esophagus, in combination with compatible clinical presentation, histopathological findings, or other immunoserological tests.] If the criteria are fulfilled, patients will be categorized into the nonbullous phenotype (no history and no current blistering on the skin) or the bullous phenotype. 4. DIF results of the healthy skin biopsy (taken as normal procedure for diagnosis) must be positive in all patients. 5. Active disease with skin lesions.

Exclusion criteria

Exclusion criteria: potential subject who meets any of the following criteria will be excluded from participation in this study: 1. The use of systemic immunosuppressive medication, such as prednisolone (>0.3mg/kg/day), methotrexate, azathioprine or dapsone (see guideline Feliciani et al)5 within the last 4 weeks before the sample collection. Prednisolone in a dosage ¡Ü 0.3 mg/kg/day is allowed. 2. Application of topical potent corticosteroids on the skin within the last week. 3. cognitively incompetent (psycho)geriatric patients

Design outcomes

Primary

MeasureTime frame
The difference in gene expression in nonbullous and bullous pemphigoid patients will be analyzed using principle component analysis. Furthermore, the expression levels of surface markers and proteins on eosinophils will be compared between the two pemphigoid variants.

Contacts

Public ContactAniek Lamberts
m.a.lamberts@umcg.nl050 3612440

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)